Patent: 10,213,444
✉ Email this page to a colleague
Summary for Patent: 10,213,444
Title: | Composition and method for treating bipolar disorder |
Abstract: | Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combination therapy of minocycline and acetylsalicylic acid delivered in doses that improve metabolic function and/or exert immune-modulating and/or anti-inflammatory effects. Also disclosed is a method for treating individuals suffering from the indicated disorders. |
Inventor(s): | Drevets; Wayne Curtis (Newton, PA), Yates; William Robert (Tulsa, OK), Savitz; Jonathan Bradley (Tulsa, OK), Preskorn; Sheldon H. (Wichita, KS) |
Assignee: | Laureate Institute For Brain Research (Tulsa, OK) |
Application Number: | 15/532,851 |
Patent Claims: | see list of patent claims |
Details for Patent 10,213,444
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | 11/14/2001 | ⤷ Try a Trial | 2034-12-04 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2034-12-04 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2034-12-04 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2034-12-04 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2034-12-04 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 11/23/2015 | ⤷ Try a Trial | 2034-12-04 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 03/09/2016 | ⤷ Try a Trial | 2034-12-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |